Journal: Pancreas

Article Title: Knockdown of Lymphoid Enhancer-binding Factor 1 Inhibits Pancreatic Adenocarcinoma Growth and Neoangiogenesis by Curbing Notch1 and Nuclear Factor Kappa B Signaling Pathways

doi: 10.1097/MPA.0000000000002562

Figure Lengend Snippet: Knockdown of LEF1 induces apoptosis in PAAD cells. A–C, Flow cytometry detection of apoptosis and apoptosis rate statistics: apoptosis rate was higher in AsPC-1/shLEF1 and BxPC-3/shLEF1. D–F, Calcein AM/PI staining assay results and statistics: the live cells decreased while the dead cells increased in AsPC-1/shLEF1 and BxPC-3/shLEF1. G, ATP production assay: the ATP production decreased in AsPC-1/shLEF1 and BxPC-3/shLEF1. H, LDH release assay showed an increase in LDH release in AsPC-1/shLEF1 and BxPC-3/shLEF1. I–M, WB results and quantitative analysis: the level of Bcl-2 protein decreased in AsPC-1/shLEF1 and BxPC-3/shLEF1, while BAX, Cleaved caspase-3 and Cleaved caspase-9 increased (n = 3, * P <0.05, ** P <0.01).

Article Snippet: The first antibodies were as follows: LEF1 (ab137872, 1:1000, Abcam), proliferating cell nuclear antigen (PCNA, ab29, 1:1000, Abcam), MMP-2 (4022S, 1:1000, CST), MMP-9 (3852S, 1:1000, CST), BAX (2772S, 1:1000, CST), Bcl-2 (15071S, 1:1000, CST), Cleaved caspase-3 (9661S, 1:1000, CST), Cleaved caspase-9 (9509S, 1:1000, CST), vascular endothelial growth factor-A (VEGFA, ab214424, 1:1000, Abcam), total Notch1 (ab52627, 1:1000, Abcam), NICD (4147, 1:1000, CST), Hes1 (ab71559, 1:1000, Abcam), Hey1 (ab235173, 1:1000, Abcam), Jagged1 (ab300561, 1:1000, Abcam), P65 (ab32536, 1:1000, Abcam), p-P65 (3033S, 1:1000, CST), GAPDH (5174S, 1:5000, CST), HRP-anti-Rabbit (A0362, 1:1000, Beyotime), HRP-anti-Mouse (A0350, 1:1000, Beyotime).

Techniques: Knockdown, Flow Cytometry, Staining, Lactate Dehydrogenase Assay

Journal: BMC Cancer

Article Title: Comparative study of clinical features, pathology, and immunophenotype between HIV-related cutaneous and visceral Kaposi’s sarcoma

doi: 10.1186/s12885-026-15910-w

Figure Lengend Snippet: Immunohistochemical Features. The left panel shows the cutaneous group, specifically from the shoulder skin, and the right panel shows the visceral group, specifically from an inguinal lymph node. Both panels display the immunohistochemical expression of PD-1, PD-L1, CyclinD1, RB, and BCL-2. Among these, PD-1 showed positivity in lymphocytes within the tumor stroma; PD-L1 showed membrane positivity in tumor cells; CyclinD1 and RB showed nuclear positivity; and BCL-2 showed cytoplasmic positivity

Article Snippet: Sections were incubated with rabbit anti-human antibodies against CyclinD1 (SP4), Rb (13A10), BCL-2 (124), P53 (BP-53-12), PD-1 ((2E5), PD-L1 (ZR3), Ki-67 (MIB-1), and, CD34 (QBEnd10) (from Gene Tech, Shanghai, China), HHV8 (13B10) (from zsbio, Beijing, China) for 25 min at room temperature.

Techniques: Immunohistochemical staining, Expressing, Membrane

Journal: bioRxiv

Article Title: Confirmatory evidence that miR-15a and miR-16 regulate BCL2 at the post-transcriptional level

doi: 10.64898/2026.03.02.708996

Figure Lengend Snippet: (A) Relative expression of miR-16-5p measured by RT-qPCR in MEG-01 wild-type (WT) cells transfected with miR-15a or miR-16-1 mimics, corresponding antisense oligonucleotides (AS), or their combinations. Data represent three independent experiments. **** p < 0.001. (B) Relative BCL2 mRNA expression in the same experimental conditions, determined by RT-qPCR using the 2^−ΔCt formula and actin as the reference gene. (C) Semi-quantitative RT-PCR analysis of BCL2 mRNA levels in MEG-01 cells under the indicated conditions, normalized to actin expression. (D) Western blot analysis of BCL2 protein expression in MEG-01 cells, with GAPDH used as a loading control.

Article Snippet: Membranes were blocked and incubated with a mouse monoclonal anti-BCL2 antibody (Santa Cruz Biotechnology) overnight at 4°C.

Techniques: Expressing, Quantitative RT-PCR, Transfection, Western Blot, Control